Treatment of acute ischemic stroke with piracetam

Stroke

Volumn 28, Issue 12, 1997, Pages 2347-2352

  De Deyn, Peter Paul ^d   De Reuck, Jacques ^a   Deberdt, Walter ^b   Vlietinck, Robert ^e   Orgogozo, Jean Marc ^c   Raoult, B ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UCB PHARMA   (Belgium)

^c HÔPITAL PELLEGRIN   (France)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e Building S3 ^*

Author keywords

Cerebral ischemia; Clinical trials; Neuroprotection; Piracetam

Indexed keywords

PIRACETAM; PLACEBO;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN PERFUSION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MEMBRANE FLUIDITY; NEUROPROTECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

EID: 0031439419     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.12.2347     Document Type: Article

References (26)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A, Woo J. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333: 1588-1593.
3. Platt D, Horn J, Summa J-D, Schmitt-Rüth B, Reintern B, Kauntz J, Krönert E. Zur Wirksamkeit von Piracetam bei geriatrischen Patienten mit akuter zerebraler Ischämie. Eine Klinisch kontrollierte Doppelblindstudie. Medwelt. 1992;43:181-190.
4. Heiss W-D, Ilsen HW, Wagner R, Pawlik G, Wienhard K. Remote functional depression of glucose metabolism in stroke and its alteration by activating drugs. In: Heiss W-D, Phelps ME, eds. Positron Emission Tomography of the Brain. Berlin Heidelberg: Springer-Verlag; 1983:162-168.
5. Herrschaft H. Die Wirksamkeit von Piracetam bei der akuten zerebralen Ischämie des Menschen: Klinisch kontrollierte Doppelblindstudie Piracetam/10% Dextran 40 versus 10% Dextran 40/Placebo. Med Klin. 1988;83:667-677.
6. Giurgea C, Mouravieff-Lesuisse F, Leemans R. Corrélations électro-pharmacologiques au cours de l'anoxie oxyprive chez le lapin en respiration libre ou artificielle. Rev Neurol. (Paris). 1970; 122:484-486.
7. 31P nuclear magnetic resonance and conformational analysis. Biochem Pharmacol. 1995;50:1129-1134.
8. Müller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse, rat and human brain. Biochem Pharmacol. 1997;53:135-140.
9. Benzi G, Pastoris O, Villa RF, Gruffrida RM. Influence of aging and exogenous substances on cerebral energy metabolism in posthypoglycemic recovery. Biochem Pharmacol. 1985;34:1477-1483.
10. 3H-glutamate sites. Arzneimittelforschung. 1985;35: 1350-1352.
11. Nickolson VJ, Wolthuis OL. Effect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism: comparison with naftidrofuryl and metamphetamine. Biochem Pharmacol. 1976; 25:2241-2244.
12. Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon M. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology. 1993;43:301-305.
13. Rosenhall U, Deberdt W, Frieberg U, Kerr A, Oosterveld W. Piracetam in patients with chronic vertigo: results of a double-blind, placebo-controlled study. Clin Drug Invest. 1996;11:251-260.
14. Brown P, Steiger MJ, Thompson PD, Rothwell JC, Day BL, Salina M, Waegemans T, Marsden CD. Effectiveness of piracetam in cortical myoclonus. Mov Disord. 1993;8:63-68.
15. Enderby P, Broeckx J, Hospers W, Schildermans F, Deberdt W. Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study. Clin Neuropharmacol. 1994; 17:320-331.
16. Hüber W, Willmes K, Poeck K, Van Vleymen B, Deberdt W. Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study. Arch Phys Med Rehabil. 1997;78:245-250.
17. Orgogozo J-M, Dartigues JF. Clinical trials in brain infarction. In: Battistini N, Fiorani P, Courbier R, Plum F, Fieschi C, eds. Acute Brain Ischemia: Medical and Surgical Therapy. New York, NY: Raven Press (Serono Symposia Publications); 1986;32:201-208.
18. Guidelines for Good Clinical Practice. EC Directive 91/507/EEC; July 19, 1991.
19. Teasdale G, Jennett B. Assessment of coma and impaired conciousness: a practical scale. Lancet. 1974;2:81-83.
20. Wade DT, Hewer RL. Functional abilities after stroke: measurement, natural history and prognosis. J Neurol Neurosurg Psychiatry. 1987;50:177-182.
21. De Haan R, Horn J, Limburg M, Van Der Meulen J, Bossuyt P. A comparison of five stroke scales with measures of disability, handicap and quality of life. Stroke. 1993;24:1178-1181.
22. Trust Study Group. Randomised double-blind, placebo-controlled trial of nimodipine in acute stroke. Lancet. 1990;336:1205-1209.
23. Granger C, Dewis LS, Peters MC, Sherwood C, Barrett J. Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil. 1979;60:14-17.
24. Mohr JP, Orgogozo JM, Harrison MJG, Hennerici M, Wahlgren NG, Gelmers JH, Martinez-Vila E, Dycka J, Tettenborn D. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis. 1994;4:177-210.
25. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
26. Grotta JC. Post-stroke management concerns and outcomes. Geriatrics. 1988;43:40-47.